35Pharma

Learn more
information at:

https://diabetesjournals.org/diabetes/article/73/Supplement_1/298-OR/155362/298-OR-Precision-Engineered-Activin-and-GDF-Ligand

About 35Pharma

35Pharma is a clinical-stage biopharmaceutical company focused on developing best-in-class transforming growth factor-beta (TGF-beta) superfamily ligand traps for pulmonary hypertension, obesity and cardiometabolic diseases. 35Pharma leverages its scientific leadership in TGF-beta biology, combined with superior protein engineering, to discover innovative compounds that selectively and potently neutralize validated pathological TGF-beta superfamily ligands, while sparing beneficial homeostatic ligands. For more information, please visit www.35pharma.com

Contact

Julia Schoelermann,  
VP Corporate Development, 35Pharma
info@35pharma.com

To receive our press releases, please subscribe to our mailing list

35Pharma is a biopharmaceutical company focused on designing and developing innovative biologics for diseases with high unmet medical need.

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.

Precision-Engineered Activin and GDF Ligand Trap HS235: A Novel Lean Mass-Preserving Treatment for Obesity.

Other publications

HS235, a Precision-Engineered Activin and GDF Ligand Trap, Is A Novel Lean Mass-Preserving Treatment for Obesity.

HS235, a Novel Activin and GDF Ligand Trap, Is Efficacious in a Model of Obesity-Related HFpEF.

Precision-Engineered Activin and GDF Ligand Trap HS235: A Novel Lean Mass-Preserving Treatment for Obesity.

Subscribe